Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: Effect of N-acetyl transferase polymorphisms (original) (raw)

The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases

L. Kadasi, T. Koller

Bratislavské lekárske listy, 2013

View PDFchevron_right

Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease

Rebecca Roberts, Richard Gearry, Murray Barclay

Alimentary Pharmacology and Therapeutics, 2003

View PDFchevron_right

Thiopurine S -methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients

D. Vlachodimitropoulos, Ioanna Panayotou

Journal of Clinical Pharmacy and Therapeutics, 2010

View PDFchevron_right

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations

Johanna Escher

Digestive and Liver Disease, 2005

View PDFchevron_right

On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance

Ad van Bodegraven

Current Drug Metabolism, 2009

View PDFchevron_right

Association between Thiopurine S-methyltransferase Polymorphisms and Thiopurine-Induced Adverse Drug Reactions in Patients with Inflammatory Bowel Disease: A Meta-Analysis

Son Duong

PloS one, 2015

View PDFchevron_right

Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease

Sven Almer

Gut, 2006

View PDFchevron_right

Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease

Andre Van Rij

Inflammatory bowel diseases, 2018

View PDFchevron_right

Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population

Aldis Pukitis

Therapeutic Advances in Gastroenterology

View PDFchevron_right

Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece

Elias Kouroumalis

European Journal of Gastroenterology & Hepatology, 2017

View PDFchevron_right

Thiopurine S-Methyltransferase Gene Polymorphisms in a Healthy Slovak Population and Pediatric Patients with Inflammatory Bowel Disease

Alica Chocholova

Nucleosides, Nucleotides and Nucleic Acids, 2013

View PDFchevron_right

Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy

Salvatore Cucchiara

Alimentary Pharmacology & Therapeutics, 2007

View PDFchevron_right

TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

Prateek Bhatia

2021

View PDFchevron_right

Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients

Renata Fróes

World journal of gastroenterology : WJG, 2014

View PDFchevron_right

Thiopurines in inflammatory bowel disease: New strategies for optimization of pharmacotherapy?

Anthony Lopez

Current Gastroenterology Reports, 2006

View PDFchevron_right

A Practical Non-Extraction Direct Liquid Chromatography Method for Determination of Thiopurine S-Methyltransferase Activity in Inflammatory Bowel Disease

Amir Kiani

Acta medica Iranica, 2017

View PDFchevron_right

Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine

Simon Campbell

Alimentary Pharmacology and Therapeutics, 2002

View PDFchevron_right

Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease

Loredana Serpe

Alimentary Pharmacology & Therapeutics, 2009

View PDFchevron_right

Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease

Themos Dassopoulos

Clinical Gastroenterology and Hepatology, 2004

View PDFchevron_right

Biomarker-based thiopurine therapy for inflammatory bowel disease

Momir Mikov

Macedonian Pharmaceutical Bulletin

View PDFchevron_right

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease

Richard Gearry

Journal of Gastroenterology and Hepatology, 2005

View PDFchevron_right

Allelic variants of the thiopurine s-methyltranferase deficiency in patients with ulcerative colitis and in healthy controls

Cesar Diaz

The American Journal of Gastroenterology, 2000

View PDFchevron_right

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease

Paul Seed

Alimentary Pharmacology and Therapeutics, 2002

View PDFchevron_right

Pharmacogenetics of thiopurines: can posology be guided by laboratory data?

Tullio Giraldi

Radiol, 2004

View PDFchevron_right

Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients

Luis Rodrigo

The American journal of gastroenterology, 2006

View PDFchevron_right